Corcept Therapeutics Incorporated cash flow to debt ratio of 2.33K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Corcept Therapeutics Incorporated's free cash flow has decreased 27.62% from $195.90M last year to $141.78M, signaling decreasing performance

Corcept Therapeutics Incorporated's debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Corcept Therapeutics Incorporated's debt has decreased relative to shareholder equity from 0.01 last year to 0.01 today, signaling strengthened financials

Corcept Therapeutics Incorporated has a net cash position, so leverage is healthy.

Corcept Therapeutics Incorporated earns at least as much interest as it pays. Interest obligations are fully covered.

Corcept Therapeutics Incorporated's profit margin was 20.70% last year and is 16.81% this year, signaling decreasing performance

Corcept Therapeutics Incorporated's short-term assets of $485.46M exceed its short-term liabilities of $166.09M

Corcept Therapeutics Incorporated's return on assets of 15.67% is higher than the 5.00% threshold, indicating efficient asset utilization

Corcept Therapeutics Incorporated's return on equity of 22.94%, is higher than 15.00%, indicating good performance

Corcept Therapeutics Incorporated's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Corcept Therapeutics Incorporated had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Corcept Therapeutics Incorporated has positive free cash flow, indicating the company generates cash after capital expenditures

Corcept Therapeutics Incorporated has a free cash flow yield of 1.80%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Corcept Therapeutics Incorporated's yearly earnings has decreased 28.68% since last year from $139.73M to $99.65M, signaling decreasing performance

Corcept Therapeutics Incorporated's yearly revenue has increased 12.79% since last year from $675.04M to $761.41M, signaling increasing performance

ROIC 12.92% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Corcept Therapeutics Incorporated's 3-year revenue CAGR of 23.74% is positive, indicating growing revenue over the past 3 years

Corcept Therapeutics Incorporated had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Corcept Therapeutics Incorporated had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Corcept Therapeutics Incorporated is overvalued relative to its fair value price of 16.23 based on Base Cash Flow Valuation (DCF) model

Corcept Therapeutics Incorporated has an earnings yield of 2.09%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Corcept Therapeutics Incorporated is overvalued relative to its fair value price of 7.04 based on Base EBITDA Valuation model

Corcept Therapeutics Incorporated has an EV/EBITDA ratio of 109.73x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Corcept Therapeutics Incorporated is overvalued relative to its fair value price of 30.04 based on Base Earnings Fair Value model

Corcept Therapeutics Incorporated's earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Corcept Therapeutics Incorporated has a price-to-book ratio of 9.31x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Corcept Therapeutics Incorporated has a price-to-sales ratio of 8.05x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue